EUVIMEDSkopri EUVIMED
KohortenstudieOpen access

Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study

Kyungseon Choi iD, Sang Jun Park iD, Sola Han iD, Yongseok Mun iD, Da Yun Lee iD, Dong-Jin Chang iD, Seok Kim iD, Sooyoung Yoo iD, Se Joon Woo iD, Kyu Hyung Park iD, Hae Sun Suh iD

JMIR Public Health and Surveillance · 2023-12-08 · 9 · e49852

DOI: 10.2196/49852 ↗

At a glance

Kohortenstudie in JMIR Public Health and Surveillance, published online on 2023-12-08. Written by Kyungseon Choi and 10 co-authors. Institution: Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea. Major MEDLINE topics: Financial Stress, Macular Degeneration. Cited 11 times so far (Crossref); 30 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Exudative age-related macular degeneration (AMD), one of the leading causes of blindness, requires expensive drugs such as anti–vascular endothelial growth factor (VEGF) agents. The long-term regular use of effective but expensive drugs causes an economic burden for patients with exudative AMD. However, there are no studies on the long-term patient-centered economic burden of exudative AMD after reimbursement of anti-VEGFs.

Objective

This study aimed to evaluate the patient-centered economic burden of exudative AMD for 2 years, including nonreimbursement and out-of-pocket costs, compared with nonexudative AMD using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).

Methods

This retrospective cohort study was conducted using the OMOP CDM, which included 2,006,478 patients who visited Seoul National University Bundang Hospital from June 2003 to July 2019. We defined the exudative AMD group as patients aged >50 years with a diagnosis of exudative AMD and a prescription for anti-VEGFs or verteporfin. The control group was defined as patients aged >50 years without a diagnosis of exudative AMD or a prescription for anti-VEGFs or verteporfin. To adjust for selection bias, controls were matched by propensity scores using regularized logistic regression with a Laplace prior. We measured any medical cost occurring in the hospital as the economic burden of exudative AMD during a 2-year follow-up period using 4 categories: total medical cost, reimbursement cost, nonreimbursement cost, and out-of-pocket cost. To estimate the average cost by adjusting the confounding variable and overcoming the positive skewness of costs, we used an exponential conditional model with a generalized linear model.

Results

We identified 931 patients with exudative AMD and matched 783 (84.1%) with 2918 patients with nonexudative AMD. In the exponential conditional model, the total medical, reimbursement, nonreimbursement, and out-of-pocket incremental costs were estimated at US $3426, US $3130, US $366, and US $561, respectively, in the first year and US $1829, US $1461, US $373, and US $507, respectively, in the second year. All incremental costs in the exudative AMD group were 1.89 to 4.25 and 3.50 to 5.09 times higher in the first and second year, respectively, than those in the control group (P

Subjects

MeSH terms (MEDLINE)

Financial StressMacular DegenerationHumansPatient-Centered CareRetrospective StudiesVerteporfinMiddle Aged

Author keywords

age-related macular degenerationblindnesscommon data modelcost of illnesseconomic burdenretrospective cohort study

Substances

Verteporfin

Authors and institutions

  • Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
  • Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Health Outcomes Division, College of Pharmacy, University of Texas at Austin, Austin, TX, United States.
  • Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID profiles: Kyungseon Choi, Sang Jun Park, Sola Han, Yongseok Mun, Da Yun Lee, Dong-Jin Chang, Seok Kim, Sooyoung Yoo, Se Joon Woo, Kyu Hyung Park, Hae Sun Suh

Cite

APA

Choi, K., Park, S. J., Han, S., Mun, Y., Lee, D. Y., Chang, D. J., Kim, S., Yoo, S., Woo, S. J., Park, K. H., & Suh, H. S. (2023). Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study. JMIR Public Health and Surveillance, 9, e49852. https://doi.org/10.2196/49852

Vancouver

Choi K, Park SJ, Han S, Mun Y, Lee DY, Chang DJ, et al. Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study. JMIR Public Health and Surveillance. 2023;9:e49852. doi:10.2196/49852

BibTeX
@article{Choi2023,
  author = {Choi, Kyungseon and Park, Sang Jun and Han, Sola and Mun, Yongseok and Lee, Da Yun and Chang, Dong-Jin and Kim, Seok and Yoo, Sooyoung and Woo, Se Joon and Park, Kyu Hyung and Suh, Hae Sun},
  title = {Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study},
  journal = {JMIR Public Health and Surveillance},
  year = {2023},
  volume = {9},
  pages = {e49852},
  doi = {10.2196/49852}
}
Start for free →